ATE439142T1 - Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung - Google Patents

Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung

Info

Publication number
ATE439142T1
ATE439142T1 AT01901920T AT01901920T ATE439142T1 AT E439142 T1 ATE439142 T1 AT E439142T1 AT 01901920 T AT01901920 T AT 01901920T AT 01901920 T AT01901920 T AT 01901920T AT E439142 T1 ATE439142 T1 AT E439142T1
Authority
AT
Austria
Prior art keywords
fibrinogen
combination
factor viia
bleeding
treatment
Prior art date
Application number
AT01901920T
Other languages
English (en)
Inventor
John Hess
Original Assignee
Us Army Med Res Mat Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Med Res Mat Command filed Critical Us Army Med Res Mat Command
Application granted granted Critical
Publication of ATE439142T1 publication Critical patent/ATE439142T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01901920T 2001-01-10 2001-01-10 Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung ATE439142T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/000725 WO2002055102A1 (en) 2001-01-10 2001-01-10 Compositions for treatment of hemorrhaging with activated factor viia in combination with fibrinogen

Publications (1)

Publication Number Publication Date
ATE439142T1 true ATE439142T1 (de) 2009-08-15

Family

ID=21742239

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01901920T ATE439142T1 (de) 2001-01-10 2001-01-10 Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung

Country Status (8)

Country Link
EP (1) EP1351705B1 (de)
AT (1) ATE439142T1 (de)
AU (1) AU2001227771B2 (de)
CA (1) CA2437024A1 (de)
DE (1) DE60139574D1 (de)
DK (1) DK1351705T3 (de)
ES (1) ES2331461T3 (de)
WO (1) WO2002055102A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
FR3026644B1 (fr) * 2014-10-07 2018-01-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Colle biologique et son utilisation comme medicament
IL247821A0 (en) 2016-09-14 2017-01-31 Omrix Biopharmaceuticals Ltd Adhesive preparations and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
EP0885020A1 (de) * 1996-02-20 1998-12-23 Cohesion Corporation Verbindungen zum gewebeverschluss und methoden zu deren gebrauch
HUP9700603A3 (en) * 1996-03-20 2001-08-28 Baxter Ag Pharmaceutical preparation for the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
EP1351705A1 (de) 2003-10-15
DE60139574D1 (de) 2009-09-24
WO2002055102A1 (en) 2002-07-18
DK1351705T3 (da) 2009-11-02
AU2001227771B2 (en) 2007-05-31
CA2437024A1 (en) 2002-07-18
EP1351705B1 (de) 2009-08-12
ES2331461T3 (es) 2010-01-05

Similar Documents

Publication Publication Date Title
Bilgili et al. Hemostatic efficacy of Ankaferd Blood Stopper® in a swine bleeding model
ATE292979T1 (de) Verwendung von aktiviertem protein-c zur behandlung überschiessender blutgerinnung bei sepsis
Sterling et al. Hemostasis in burn surgery—a review
CY1113705T1 (el) Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων
Tang et al. Use of tranexamic acid to reduce bleeding in burns surgery
DE602006021290D1 (de) Modulator von coagulationskaskaden und fibrinolytischen kaskaden
DE60139574D1 (de) Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung
Aleksandar et al. Effect of fibrin vs cellulose based haemostatic agents with traditional haemostatic procedures in thyroid surgery
Seguchi et al. Hemostatic efficacy of oxidized regenerated cellulose powder in Le fort 1 osteotomy
Shetty Effectiveness of intravenous haemocoagulase on haemorrhage control in bi-maxillary orthognathic surgery—a prospective, randomised, controlled, double-blind study
Tokgöz et al. Protective value of a folkloric medicinal plant extract against mortality and hemorrhage in a life-threatening renal trauma model
Irvine et al. Hand venous hypertension complicating arterio‐venous fistula construction for haemodialysis
ATE171071T1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
Tham et al. Limited microsurgical arteriolysis for complications of digital vasospasm
Rothwell et al. ε-Amino caproic acid additive decreases fibrin bandage performance in a swine arterial bleeding model
DE60040236D1 (de) Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen
Fan et al. Haemostatic efficacy of an ethyl-2-cyanoacrylate-based aerosol in combination with tourniquet application in a large wound model with an arterial injury
Rath et al. Survival of a free musculocutaneous flap after early loss of arterial blood supply
Kuppusamy et al. Hemostatic agents-A review.
Reddy et al. Forearm compartment syndrome following puncture of haemodialysis access fistula
Ghoz et al. Use of a thrombin fibrin sealant in reducing blood loss in revision hip arthroplasty
Moreira et al. Wound management
Akpancar et al. Effects of tourniquet in total knee arthroplasty
Ito Hemostatic Agents in Gynecologic Surgery
Moraru et al. Burn Management using Enzymatic Debridement with Bromelain enriched Enzyme Mixture (Nexobrid™)-Case Series

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1351705

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1351705

Country of ref document: EP